BidaskClub Upgrades Inogen (INGN) to “Buy”

BidaskClub upgraded shares of Inogen (NASDAQ:INGN) from a hold rating to a buy rating in a research report released on Saturday.

Several other brokerages have also recently weighed in on INGN. Zacks Investment Research raised shares of Inogen from a hold rating to a buy rating and set a $131.00 price objective on the stock in a research note on Thursday, November 9th. Leerink Swann reissued an outperform rating and issued a $120.00 price objective (up previously from $115.00) on shares of Inogen in a research note on Wednesday, November 8th. Finally, Needham & Company LLC boosted their price objective on shares of Inogen from $108.00 to $125.00 and gave the stock a strong-buy rating in a research note on Wednesday, November 8th. Three investment analysts have rated the stock with a hold rating, four have assigned a buy rating and one has assigned a strong buy rating to the stock. The stock presently has an average rating of Buy and a consensus price target of $103.14.

Shares of Inogen (INGN) opened at $117.90 on Friday. Inogen has a one year low of $66.51 and a one year high of $130.05. The firm has a market cap of $2,460.00, a price-to-earnings ratio of 82.45, a P/E/G ratio of 3.96 and a beta of 1.02.

In related news, EVP Byron Myers sold 35,000 shares of the business’s stock in a transaction on Friday, November 17th. The shares were sold at an average price of $116.77, for a total value of $4,086,950.00. Following the transaction, the executive vice president now owns 48,600 shares in the company, valued at $5,675,022. The transaction was disclosed in a document filed with the SEC, which is available through this link. Also, Director Heath Lukatch sold 2,500 shares of the business’s stock in a transaction on Friday, December 1st. The shares were sold at an average price of $126.40, for a total transaction of $316,000.00. The disclosure for this sale can be found here. In the last 90 days, insiders sold 150,499 shares of company stock worth $17,594,143. 5.31% of the stock is owned by company insiders.

Hedge funds have recently added to or reduced their stakes in the stock. Lenox Wealth Advisors Inc. acquired a new position in Inogen in the fourth quarter valued at $100,000. Steward Partners Investment Advisory LLC lifted its holdings in Inogen by 1,000.0% in the fourth quarter. Steward Partners Investment Advisory LLC now owns 1,100 shares of the medical technology company’s stock valued at $130,000 after buying an additional 1,000 shares during the period. Simplex Trading LLC acquired a new position in Inogen in the fourth quarter valued at $153,000. Ameritas Investment Partners Inc. lifted its holdings in Inogen by 6.1% in the second quarter. Ameritas Investment Partners Inc. now owns 1,495 shares of the medical technology company’s stock valued at $143,000 after buying an additional 86 shares during the period. Finally, LS Investment Advisors LLC raised its holdings in shares of Inogen by 138.6% during the fourth quarter. LS Investment Advisors LLC now owns 1,515 shares of the medical technology company’s stock valued at $180,000 after purchasing an additional 880 shares during the period.

COPYRIGHT VIOLATION WARNING: This report was originally published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this report on another website, it was copied illegally and republished in violation of U.S. and international copyright and trademark law. The original version of this report can be accessed at https://www.dispatchtribunal.com/2018/02/14/bidaskclub-upgrades-inogen-ingn-to-buy.html.

About Inogen

Inogen, Inc is a medical technology company. The Company develops, manufactures and markets portable oxygen concentrators used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions. The Company’s Inogen One systems concentrate the air around the patient to offer a single source of supplemental oxygen anytime, anywhere with a portable device.

Analyst Recommendations for Inogen (NASDAQ:INGN)

Receive News & Ratings for Inogen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inogen and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply